17 October 2017

GlaxoSmithKline wins first-ever nod for blockbuster Shingrix vaccine

Just as GlaxoSmithKline nears a decision from the U.S. FDA for its key shingles vaccine, Shingrix, Canada has become the first country to approve the shot. The Canadian approval covers people 50 years or older, as a prevention tool against the painful condition that's caused by latent varicella infection. It's based on a phase 3 trial that involved 37,000 people, 2,100 of whom were enrolled at 31 sites across Canada. Source: FiercePharma 17/10/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).